Bold claim: the Brigham-Dana-Farber split isn’t just a dispute over staff—it’s a precursor to a broader reshaping of Boston’s cancer care landscape. And this is the part most people miss: the fight isn’t only about where clinicians work; it’s about who controls access to the most advanced cancer treatment in the region.
A recent internal notice reveals Brigham Health, backed by its parent Mass General Brigham, intends to phase out Dana-Farber–employed physician assistants (PAs) from Brigham facilities, with the plan to complete the transition by year’s end. Dana-Farber staff are employed by Dana-Farber, but Brigham contracts with them to operate inside Brigham hospitals. The aim, according to the message from Dana-Farber’s chief medical officer, Dr. Craig Bunnell, was an orderly ramp-down that would minimize disruption. Instead, Brigham signaled a different path, indicating the plan diverged from the mutually agreed transition approach.
Mass General Brigham soon countered by inviting Dana-Farber PAs to join the Brigham, promising an end to the employment limbo. In an internal note, MGB executives wrote, “We want you on our team.”
The feud has deep roots. For years, Dana-Farber has pursued its own hospital and strategic vision, while Mass General Brigham has integrated its flagship hospitals—creating a competitive dynamic that many observers see as fueling a broader cancer-care arms race. This isn’t just about staffing; it’s about who leads the region’s cancer ecosystem and how much investment the system will commit to retain that leadership.
Health-care economist Gary J. Young of Northeastern University described the move as the kind of dynamic that could spur heavy investment in technology, talent, and top oncology talent. In the short term, that may raise costs as both systems bid for high-priced specialists and new capabilities. In the longer term, a Boston-centric consolidation of cancer care could pull high-margin cases away from community hospitals, potentially weakening already fragile players and lifting overall health-care spending.
Evidence of the spending race is already visible. Mass General Brigham is reportedly offering additional compensation to its physician assistants who take shifts in a new MGB cancer unit at the Brigham. Public statements from both hospitals emphasize patient care, but behind the scenes the negotiations remain unsettled.
Historically, the two systems have operated in tandem—Dana-Farber patients received outpatient chemotherapy at Dana-Farber while inpatient care occurred at Brigham and Women’s, with Dana-Farber clinicians handling oncology care during hospital stays and Brigham clinicians covering surgical, radiation, radiology, and pathology services. Unraveling these intertwined arrangements will be challenging and could presage further tensions.
As of now, neither side has finalized a transition-services agreement, leaving the timeline and logistics of dismantling shared workflows unclear. Dana-Farber has been working toward minimizing staff disruption and preserving patient care, but Mass General Brigham’s recent actions represent a notable shift in expectations.
MGB argues the move is a necessary measure to prepare for Dana-Farber’s uncertain patient and staff movements, emphasizing the need for stable, well-staffed inpatient oncology teams by 2028. Yet the exact number of affected PAs remains unknown, and it’s unclear what assurances exist for those Dana-Farber staff who choose to stay with the cancer-focused institution.
Even if MGB lures more clinicians to its internal cancer program, that program itself is in flux. Notably, a majority of the roughly 200 advanced practice providers within the Mass General Brigham Cancer Institute recently signed union cards with the Massachusetts Nurses Association, signaling potential labor tensions ahead.
Beyond personnel, both organizations are expanding their cancer-care ambitions—opening new units, pursuing large philanthropic gifts, and seeking regulatory and other approvals for ambitious plans. The financial stakes are high: Brigham has highlighted its share of cancer-related surgeries and its desire to retain that volume, while Dana-Farber’s core mission is centered on cancer as its defining focus.
Observers worry about patient experience during this transition. Officials say they aim for seamless care, but experts warn that behind-the-scenes disruptions could pose real challenges for patients and insurers when determining which facility their members can access.
In short, the disagreement is about more than staffing. It’s about control, investment, and the future map of cancer care in Boston—and the industry is watching closely to see who will set the terms for care delivery and financing in the years ahead.
Would you agree that this rivalry will ultimately drive better care, or do you fear it could create unnecessary fragmentation for patients? What outcome would you prefer to see to ensure patients experience truly seamless, high-quality cancer treatment across institutions?
Jessica Bartlett can be reached at jessica.bartlett@globe.com. Follow her @ByJessBartlett.
